Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03931720|
Recruitment Status : Recruiting
First Posted : April 30, 2019
Last Update Posted : April 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Malignant Tumor||Biological: BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor|
|Estimated Study Start Date :||May 2019|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2022|
Experimental: anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)
Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
Biological: BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)
The subject will be observed for any side effects during this time and all the adverse events will be recorded.
- Occurrence of treatment related adverse events as assessed by CTCAE v4.03 [ Time Frame: 1 year ]Defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03931720
|Contact: Guangfu Li||+86 email@example.com|
|Contact: Xianfeng Feng||+86 firstname.lastname@example.org|
|Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine||Recruiting|
|Suzhou, Jiangsu, China, 215021|
|Contact: Fengchun Zhang, PhD email@example.com|